Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Stablizing an enzyme by forming a mixture – an adduct or a...
Reexamination Certificate
2004-03-01
2008-09-02
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Stablizing an enzyme by forming a mixture, an adduct or a...
C424S178100
Reexamination Certificate
active
07419811
ABSTRACT:
The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
REFERENCES:
patent: 6299876 (2001-10-01), Bagshawe
patent: 2001/0012835 (2001-08-01), Fine et al.
patent: 2007/0037269 (2007-02-01), Marliere et al.
patent: WO0188106 (2001-11-01), None
patent: WO 02/083892 (2002-10-01), None
Kossman S., Scheinberg, D., et al., Clin Can Res, vol. 5, pp. 2748-2755, Oct. 1999.
Zhu et al., JBC, vol. 275, p. 26727, 2000, abstract.
Bergman et al., Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase, 1999,Biochem. Pharmacol. 57:397-406.
Blackstock et al., Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response, 2001,Clin. Cancer Res. 7:3263-8.
Blakey et al., “Enzyme Prodrug Therapy of Cancer” Exp. Opin. Ther. Patents (Sep. 1997) 7(9) 966-977.
Estey et al., Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia, 1987,Leukemia 1:580-3.
Estey, How I treat older patients with AML, 2000,Blood 96:1670-3.
Gandhi et al, Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy, 1993,J. Clin. Oncol. 11:116-24.
Gladstone et al, “Antibody Directed Doexycytidine Kinase (DCK) Enhances the Cytotoxicity of Ara —C Towards CD33+ Leukemia Cells. Session Type: Oral Session” Blood 102(11) 138A (Nov. 16, 2003).
Goan et al, Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line, 1999,Cancer Res. 59:4204-7.
Hapke et al., Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity, 1996,Cancer Res. 56:2343-7.
Hubert et al., STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors, 1999,Proc Natl Acad SciU S A. 7:14523-8.
Iacoboni et al., High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis, 1986,J. Clin. Oncol. 4:1079-88.
Kabouridis, Biological applications of protein transduction technology, 2003,Trends in Biotechnology21:498-503.
Kakihara et al., Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia, 1998,Leuk. Lymphoma 31:405-9.
Kantarjian et al., Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia, 1986,Am. J. Med. 81:387-94.
Knecht et al., 2002, A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines,EMBO J. 21:1873-1880.
Lotfi et al., Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells, 1999,Clin. Cancer Res. 5:2438-44.
Manssoon et al., Down-regulation of deoxycytidine kinase in human leukemic cell lines resistance to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance, 2003,Biochem. Pharmacol. 65:237-247.
Owens et al., Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene, 1992,Cancer Res. 52:2389-93.
Plunkett et al., Pharmacologically directed ara-C therapy for refractory leukemia, 1985,Semin Oncol 12:20-30.
Ruiz Van Haperen et al., Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780, 1994,Cancer Res. 54:4138-43.
Sandlie and Brekke, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, 2003,Nat. Rev. Drug Discovery 2:52-62.
Stegmann et al., Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity, 1995,Blood 85:1188-94.
Van Rompay, et al., Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases, 2000,Pharmacol. Ther. 87:189-98.
Iyidogan, Pinar, et al., “Systematic Exploration of Active Site Mutations on Human Deoxycytidine Kinase Substrate Specificity,” Biochemistry, 2008, vol. 47, pp. 4711-4720.
Konrad Manfred
Lavie Arnon
Ravandi Farhad
Helms Larry R.
McDonnell Boehnen & Hulbert & Berghoff LLP
The Board of Trustees of the University of Illinois
Yao Lei
LandOfFree
Use of specifically engineered enzymes to enhance the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of specifically engineered enzymes to enhance the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of specifically engineered enzymes to enhance the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3976808